“FOR THE VERY FIRST TIME IN HUMANHISTORY, BIOLOGY HAS THEOPPORTUNITY TO BE ENGINEERING—NOT SCIENCE”
As the visionary behind NVIDIA, Jensen Huang has notonly revolutionized computing, gaming, and artificialintelligence—he’s now shaping the future of biology. Underhis leadership, NVIDIA has grown into a $2 trillionpowerhouse and emerged as a critical enabler of a newparadigm: biology as an engineerable, programmablesystem.
Huang sees biology as nature’s most powerful computingplatform—and believes that with enough computationalpower, we can simulate, understand, and ultimatelyprogram it. That belief is now materializing throughNVIDIA’s bold forays into the life sciences.
Among Huang’s most transformative initiatives is thelaunch of BioNeMo Cloud, a platform built specifically todevelop and deploy large-scale foundation models forproteins, DNA, RNA, and small molecules. With BioNeMo,researchers and startups can now tap into pretrainedgenerative models to design novel compounds, predictprotein structures, or simulate biological behavior—tasksthat were once reserved for years of wet-lab work.
NVIDIA’s strategy goes beyond infrastructure. UnderHuang’s leadership, the company has actively invested inand partnered with key players in BioPharma, signaling along-term commitment to this space. In 2023, NVIDIAmade a $50 million investment in Recursion, one of theworld’s leading AI-native biotech companies. Thepartnership combines Recursion’s massive phenomicsdatasets and lab automation with NVIDIA’s computeplatform—accelerating drug discovery at scale.
Huang has also forged deep collaborations with BioPharma leaders like Amgen, Genentech, and Evozyne, helping them integrate AI into protein engineering, antibody discovery, and molecular design. These partnerships reflect a shared vision: to bring the precision and scalability of computation into the traditionally slow, complex world of biology.
One of the most ambitious examples of this vision is thesupercomputer developed by the Novo NordiskFoundation, built using NVIDIA’s DGX platform. Designedspecifically to accelerate AI-driven drug discovery, thissystem enables Novo Nordisk to simulate, optimize, andpredict molecular interactions at a previously unthinkablescale. By running deep learning models on massive datasets—including omics, chemical structures, and real-worldclinical data—Novo Nordisk aims to cut down the timefrom target discovery to clinical trial readiness. Thisrepresents a critical leap forward in therapeuticdevelopment for complex diseases like diabetes, obesity,and cardiometabolic disorders.
At the foundation of this ecosystem lies NVIDIA hardwareand compute platforms powering some of the mostadvanced biological models in use today: AlphaFold, whichpredicts protein structures with remarkable accuracy;RoseTTAFold, which extends deep learning into multi-domain folding; and BioGPT, which models biologicallanguage for knowledge extraction and hypothesisgeneration.
This is more than digital transformation—it’s the birth of aprogrammable bioeconomy, where the design-build-testcycle of biology begins to mirror the speed andrepeatability of software engineering. In this future,diseases are not just treated—they are modeled, predicted,and increasingly engineered out of existence.
By merging the worlds of silicon and biology, Huang iscatalyzing a new era of compounding innovation—not justin code, but in cells.
